Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

J Clin Oncol. 2011 Apr 1;29(10):1232-5. doi: 10.1200/JCO.2010.33.2684. Epub 2011 Mar 7.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / economics
  • Breast Neoplasms / mortality
  • Breast Neoplasms / secondary
  • Cost-Benefit Analysis
  • Disease-Free Survival
  • Drug Costs
  • Female
  • Humans
  • Neoplasm Recurrence, Local*
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2 / analysis*
  • Risk Assessment
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Bevacizumab
  • ERBB2 protein, human
  • Receptor, ErbB-2